Naringin Dihydrochalcone (CAS 18916-17-1): A Sweetener with Biomedical Potential
Naringin Dihydrochalcone (CAS 18916-17-1) is emerging as a star ingredient, bridging the gap between natural sweetness and biomedical applications. Derived from the naringin found in citrus fruits, this compound boasts an extraordinary sweetness profile, far surpassing that of traditional sugar. Beyond its sensory appeal, Naringin Dihydrochalcone exhibits significant bioactivity, notably its ability to inhibit key enzymes, making it a valuable asset for researchers and manufacturers alike.
As a leading Naringin Dihydrochalcone supplier, NINGBO INNO PHARMCHEM CO.,LTD. offers this chemical with high purity, ensuring its efficacy in diverse applications. The compound's origin from citrus bioflavonoids lends it an aura of naturalness, appealing to consumers increasingly conscious of ingredient sourcing. Its structure, a phloretin glycoside, contributes to its unique sweetening and inhibitory properties.
One of the most significant attributes of Naringin Dihydrochalcone is its role as a CYP enzyme inhibitor. Cytochrome P450 (CYP) enzymes are critical in metabolizing a vast array of endogenous substances and xenobiotics, including drugs. By inhibiting these enzymes, Naringin Dihydrochalcone can influence pharmacokinetic profiles and is therefore of considerable interest in drug development and research. This enzymatic interaction is a key reason why many seek to purchase Naringin Dihydrochalcone for specialized studies.
Furthermore, Naringin Dihydrochalcone has shown promise in modulating cholesterol metabolism. It acts as an inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, and also inhibits ACAT (acyl-CoA:cholesterol acyltransferase) activities. These mechanisms suggest potential applications in managing lipid profiles and could be a focus for those researching cardiovascular health or metabolic disorders. The availability from a reputable Naringin Dihydrochalcone manufacturer like NINGBO INNO PHARMCHEM CO.,LTD. is crucial for such research.
The applications extend to its function as a potent artificial sweetener. Its clean taste and ability to mask bitterness make it a preferred choice in the food and beverage industry for creating low-calorie and sugar-free products. In pharmaceuticals, it enhances the palatability of medicines, a critical factor for pediatric or geriatric formulations. The prospect of buying this versatile ingredient for both sweetening and therapeutic research underscores its market value.
NINGBO INNO PHARMCHEM CO.,LTD. prides itself on being a reliable source for Naringin Dihydrochalcone. Our commitment to quality assurance and customer service ensures that our clients receive a product that meets the highest standards. Whether your focus is on developing novel sweeteners, exploring enzyme inhibition pathways, or creating more palatable pharmaceutical products, Naringin Dihydrochalcone offers a unique blend of sweetness and bioactivity. Partner with NINGBO INNO PHARMCHEM CO.,LTD. to unlock the potential of this remarkable compound.
As a leading Naringin Dihydrochalcone supplier, NINGBO INNO PHARMCHEM CO.,LTD. offers this chemical with high purity, ensuring its efficacy in diverse applications. The compound's origin from citrus bioflavonoids lends it an aura of naturalness, appealing to consumers increasingly conscious of ingredient sourcing. Its structure, a phloretin glycoside, contributes to its unique sweetening and inhibitory properties.
One of the most significant attributes of Naringin Dihydrochalcone is its role as a CYP enzyme inhibitor. Cytochrome P450 (CYP) enzymes are critical in metabolizing a vast array of endogenous substances and xenobiotics, including drugs. By inhibiting these enzymes, Naringin Dihydrochalcone can influence pharmacokinetic profiles and is therefore of considerable interest in drug development and research. This enzymatic interaction is a key reason why many seek to purchase Naringin Dihydrochalcone for specialized studies.
Furthermore, Naringin Dihydrochalcone has shown promise in modulating cholesterol metabolism. It acts as an inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, and also inhibits ACAT (acyl-CoA:cholesterol acyltransferase) activities. These mechanisms suggest potential applications in managing lipid profiles and could be a focus for those researching cardiovascular health or metabolic disorders. The availability from a reputable Naringin Dihydrochalcone manufacturer like NINGBO INNO PHARMCHEM CO.,LTD. is crucial for such research.
The applications extend to its function as a potent artificial sweetener. Its clean taste and ability to mask bitterness make it a preferred choice in the food and beverage industry for creating low-calorie and sugar-free products. In pharmaceuticals, it enhances the palatability of medicines, a critical factor for pediatric or geriatric formulations. The prospect of buying this versatile ingredient for both sweetening and therapeutic research underscores its market value.
NINGBO INNO PHARMCHEM CO.,LTD. prides itself on being a reliable source for Naringin Dihydrochalcone. Our commitment to quality assurance and customer service ensures that our clients receive a product that meets the highest standards. Whether your focus is on developing novel sweeteners, exploring enzyme inhibition pathways, or creating more palatable pharmaceutical products, Naringin Dihydrochalcone offers a unique blend of sweetness and bioactivity. Partner with NINGBO INNO PHARMCHEM CO.,LTD. to unlock the potential of this remarkable compound.
Perspectives & Insights
Future Origin 2025
“One of the most significant attributes of Naringin Dihydrochalcone is its role as a CYP enzyme inhibitor.”
Core Analyst 01
“Cytochrome P450 (CYP) enzymes are critical in metabolizing a vast array of endogenous substances and xenobiotics, including drugs.”
Silicon Seeker One
“By inhibiting these enzymes, Naringin Dihydrochalcone can influence pharmacokinetic profiles and is therefore of considerable interest in drug development and research.”